---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-22-000248"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T19:47:34.473435+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lilly Q3 2022: revenue up 2% to $6.94B, reported EPS $1.61 (+32%), Mounjaro launch strong

## Summary
- Revenue $6,941.6M (+2% reported, +7% constant currency); total volume +14%.
- Reported EPS $1.61 (+32%); non-GAAP EPS $1.98 (+12%); both inclusive of $0.06 acquired IPR&D charges.
- Mounjaro U.S. revenue $97.3M in first full quarter; plus $86.0M from Japan collaboration agreement.
- Key growth products (Verzenio, Trulicity, Mounjaro, etc.) grew 19% and represented 70% of revenue (ex-COVID antibodies).
- 2022 EPS guidance updated: reported $6.50-$6.65, non-GAAP $7.70-$7.85, inclusive of $0.67 charges.

## SEC filing metadata
- accession: 0000059478-22-000248
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947822000248/0000059478-22-000248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947822000248/lly-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-22-000248
- JSON: https://secwatch.observer/filing/0000059478-22-000248.json
- Plain text: https://secwatch.observer/filing/0000059478-22-000248.txt

## Key facts
- Earnings Releases
  ELI LILLY & Co reported the third quarter of 2022 results: revenue $6,941.6, net income 1,451.7, EPS $1.61.
  - Period: the third quarter of 2022
  - Revenue: $6,941.6
  - Net income: 1,451.7
  - EPS: $1.61
  - Result: reported results
  source text: other important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data Third Quarter % 2022 2021 Change Revenue $6,941.6 $6,772.8 2% Net Income – Reported 1,451.7 1,110.1 31% EPS – Reported 1.61 1.22 32% Net Income – Non-GAAP 1,789.2 1,614.2 11% EPS – Non-GAAP 1.98 1.77 12% A discussion of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947822000248/0000059478-22-000248-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.